Erythropoietin in patients with acute renal failure and continuous veno- venous haemofiltration

被引：13

作者：

Morgera S. ^{[1
]}

Heering P. ^{[1
]}

Szentandrasi T. ^{[1
]}

Niederau C. ^{[2
]}

Grabensee B. ^{[1
]}

机构：

[1] Dept. of Nephrology and Rheumatology, Heinrich-Heine-University, Düsseldorf

[2] Department of Clinical Biochemistry, Heinrich-Heine-University, Düsseldorf

来源：

International Urology and Nephrology | 1997年 / 29卷 / 2期

关键词：

Ferritin; Acute Renal Failure; Erythropoietin; Normal Renal Function; International Urology;

D O I：

10.1007/BF02551350

中图分类号：

学科分类号：

摘要：

Erythropoietin (Epo) is a glycoprotein hormone produced in the kidney in response to hypoxia or anaemia. In acute renal failure (ARF) anaemia also occurs and current opinion is that Epo production is depressed with inappropriately low plasma levels throughout the uraemic phase. Our study was designed to determine the excretion of Epo in patients with ARF. Fifty-nine ventilated patients were studied, 39 with ARF and continuous veno-venous haemofiltration therapy (group 1) and 13 patients with normal renal function who served as a control group (group 2). All patients with ARF were anaemic and needed a mean transfusion of 0.6 units/day. Values for vitamin B12, folic acid, serum iron end ferritin were normal. While patients with normal renal function had Epo values within the normal range, patients with ARF had significantly higher values at the onset of haemofiltration therapy. Mean EPO (mean ± SEM) values on days 0-2 were 92.6 ± 11.7 mU/ml in group 1 and 16.5 ± 6.4 mU/ml in group 2 (p<0.0002), Epo levels declined in group 1 to 49 ±10.5 mU/ml on days 9 and 10 compared to 23 ±9.1 mU/ml in group 2 (ns). These values were maintained until the end of the observation period. No differences were seen between oliguric end non-oliguric patients. Our data show that patients with ARF have increased Epo levels at the beginning of the disease with a strong tendency to decrease, suggesting that there might be inadequate Epo levels during the course of acute renal failure.

引用

页码：245 / 250

页数：5

共 10 条

[1] Erslev A.J., Caro J., Birgegard G., Silver R., Miller O., The biogenesis of erythropoietin, Exp. Hematol, 8, SUPPL., (1980)
[2] Eschbach J.W., Adamson J.W., Anaemia of end-stage renal disease, Kidney Int., 28, (1985)
[3] Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., Cotes P.M., Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis, Lancet, 2, (1986)
[4] Lipkin G.W., Kendall R.G., Russon L.J., Turney J.H., Norfolk D.R., Brownjohn A.M., Erythropoietin deficiency in acute renal failure, Nephrol. Dial. Transplant., 5, (1990)
[5] Heidenreich S., Rahn K.H., Zidek W., Erythropoietin in thrombocytopenic purpura and acute renal failure, Clin. Invest., 70, (1992)
[6] Nielsen O.J., Thaysen J.H., Erythropoietin deficiency in acute renal failure, Lancet, 1, (1989)
[7] Lipkin G.W., Kendall R.G., Haggett P., Turney J.H., Brownjohn A.M., Erythropoietin in acute renal failure, Lancet, 1, (1989)
[8] Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A., Knaus W., Schein R., Sibbald W., The ACCP/SCCM Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, Chest, 101, (1992)
[9] Nielsen O.J., Thaysen H., Erythropoietin deficiency in acute tubular necrosis, J. Int. Med., 227, (1990)
[10] Boecheva V., Mushekow V., Osichenko A., Acute renal failure and anaemia, Acute Renal Failure, 17, (1995)

← 1 →